Novo Nordisk A/S vs Pfizer Inc.: Strategic Comparison
Key Differences at a Glance
| Field | Novo Nordisk A/S | Pfizer Inc. |
|---|---|---|
| Revenue | $46.0B | $62.6B |
| Founded | 1989 | 1849 |
| Employees | 69,505 | 75,000 |
| Market Cap | $550.0B | $148.0B |
| Headquarters | Denmark | United States |
Quick Stats Comparison
| Metric | Novo Nordisk A/S | Pfizer Inc. |
|---|---|---|
| Revenue | $46.0B | $62.6B |
| Founded | 1989 | 1849 |
| Headquarters | Bagsvaerd, Denmark | New York, New York |
| Market Cap | $550.0B | $148.0B |
| Employees | 69,505 | 75,000 |
Novo Nordisk A/S Revenue vs Pfizer Inc. Revenue — Year by Year
| Year | Novo Nordisk A/S | Pfizer Inc. | Leader |
|---|---|---|---|
| 2025 | $46.0B | $62.6B | Pfizer Inc. |
| 2024 | $42.7B | $63.6B | Pfizer Inc. |
| 2023 | $34.0B | $59.6B | Pfizer Inc. |
| 2022 | N/A | $101.2B | Pfizer Inc. |
| 2021 | N/A | $81.3B | Pfizer Inc. |
Business Model Breakdown
Overview: Novo Nordisk A/S vs Pfizer Inc.
This in-depth comparison examines Novo Nordisk A/S and Pfizer Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Novo Nordisk A/S on its own, evaluating Pfizer Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Novo Nordisk A/S and Pfizer Inc. is widest.
On the headline numbers, Novo Nordisk A/S reports annual revenue of $46.0B against $62.6B for Pfizer Inc., while their respective market capitalizations stand at $550.0B and $148.0B. Novo Nordisk A/S is headquartered in Denmark and Pfizer Inc. operates from United States, and those different home markets shape how each company competes.
Novo Nordisk A/S: Novo Nordisk A/S is a public company listed on NYSE under ticker NVO. Novo Nordisk makes money by developing and selling prescription medicines for diabetes, obesity, rare blood disorders, rare endocrine disorders, and related chronic diseases.
Pfizer Inc.: Pfizer has repeatedly reinvented itself around new therapeutic waves, from industrial fermentation and penicillin to Lipitor, vaccines, COVID products, and now oncology. The 2025 profile is not a pandemic windfall story; it is a large pharmaceutical company trying to rebuild a durable growth base.
Business Models: How Novo Nordisk A/S and Pfizer Inc. Make Money
Novo Nordisk A/S and Pfizer Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Novo Nordisk A/S and Pfizer Inc..
Novo Nordisk A/S business model: Novo Nordisk operates an focused, hyper-lucrative specialty pharmaceutical business model. By dedicating extensive resources almost entirely to diabetes and obesity therapeutics, they generate staggering margins by manufacturing complex biological insulin and GLP-1 analogs, aggressively capturing global market share with unprecedented consumer demand.
Pfizer Inc. business model: Pfizer operates a prominent, volume-driven biopharmaceutical model. It relies entirely on large scale. The company does not simply rely on slow internal R&D; it operates as a substantial M&A engine, aggressively acquiring smaller biotech firms that have promising drugs, and then using its unparalleled global manufacturing and sales force to maximize the commercial revenue before the patents expire.
Competitive Advantage: Novo Nordisk A/S vs Pfizer Inc.
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Novo Nordisk A/S stack up against those of Pfizer Inc..
Novo Nordisk A/S competitive advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Pfizer Inc. competitive advantage: Pfizer advantage is scale: global regulatory expertise, manufacturing capacity, clinical development experience, commercial infrastructure, vaccine capabilities, and the ability to acquire or partner for scientific platforms.
Growth Strategy: Where Novo Nordisk A/S and Pfizer Inc. Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Novo Nordisk A/S and Pfizer Inc. each plan to expand from here.
Novo Nordisk A/S growth strategy: Novo Nordisk A/S's growth strategy centers on this advantage: Novo Nordisk's advantage is deep GLP-1 science, diabetes and obesity scale, global manufacturing, payer experience, and one of the world's strongest chronic-care franchises.
Pfizer Inc. growth strategy: Pfizer growth strategy emphasizes oncology, vaccines, internal medicine, obesity and metabolic research, business development discipline, cost reduction, and global commercial execution. Chris Boshoff became Chief Scientific Officer and President, Research & Development effective January 1, 2025.
Financial Picture: Novo Nordisk A/S vs Pfizer Inc.
A closer look at the financial trajectory of Novo Nordisk A/S and Pfizer Inc. rounds out the comparison.
Novo Nordisk A/S: Novo Nordisk A/S reported FY2025 revenue of DKK 309.064B (about $46.0B) and net income of DKK 102.434B (about $15.2B).
Pfizer Inc.: Pfizer reported $62.579 billion of FY2025 revenue, compared with $63.627 billion in FY2024 and $59.553 billion in FY2023. Net income was $7.771 billion in FY2025. Pfizer employed approximately 75,000 people worldwide as of December 31, 2025.
Company-Specific SWOT Notes
Novo Nordisk A/S
Novo Nordisk has global scale, clinical depth, and manufacturing experience in diabetes and obesity GLP-1 medicines.
A large share of investor expectations depends on continued Ozempic and Wegovy growth.
Obesity care, cardiovascular outcomes, oral formulations, and broader metabolic indications can expand the addressable market.
Rival incretin drugs, compounding, payer restrictions, safety scrutiny, and supply constraints can pressure growth.
Pfizer Inc.
Pfizer has manufacturing, regulatory, clinical, and commercial infrastructure that few competitors can match globally.
Major products face loss of exclusivity and pricing pressure, requiring strong replacement revenue.
The Seagen acquisition gives Pfizer a larger oncology platform and ADC pipeline if clinical and commercial execution succeeds.
Medicare negotiation, generic competition, and failed pipeline readouts can compress revenue and margins.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | Pfizer Inc. | Pfizer Inc. reports the larger revenue base ($62.6B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | Pfizer Inc. | Founded in 1989 vs 1849. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Pfizer Inc. | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | Pfizer Inc. | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Novo Nordisk A/S | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
Pfizer Inc. reports the larger revenue base ($62.6B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1989 vs 1849. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Novo Nordisk A/S or Pfizer Inc.?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Novo Nordisk A/S vs Pfizer Inc.
Is Novo Nordisk A/S better than Pfizer Inc.?
Verdict: Between Novo Nordisk A/S and Pfizer Inc., Pfizer Inc. is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, Pfizer Inc. comes out ahead in this Novo Nordisk A/S vs Pfizer Inc. comparison.
Who earns more — Novo Nordisk A/S or Pfizer Inc.?
Pfizer Inc. earns more with $62.6B in annual revenue versus Novo Nordisk A/S's $46.0B. Pfizer Inc. leads on total revenue based on latest verified figures.
Which company has higher revenue — Novo Nordisk A/S or Pfizer Inc.?
Novo Nordisk A/S reported $46.0B, while Pfizer Inc. reported $62.6B. The revenue leader is Pfizer Inc. based on latest verified figures.
Novo Nordisk A/S revenue vs Pfizer Inc. revenue — which is higher?
Novo Nordisk A/S revenue: $46.0B. Pfizer Inc. revenue: $46.0B. Pfizer Inc. has the larger revenue base of the two companies.
Sources & References
- Novo Nordisk A/S Corporate Website
- Novo Nordisk A/S Annual Report 2025 - Revenue and Financial Data
- sec.gov
- novonordisk.com
- SEC EDGAR: Pfizer Inc. Annual Filings (10-K, 8-K)
- Pfizer Inc. Corporate Website
- Pfizer Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- investors.pfizer.com
- pfizer.com
- investors.pfizer.com